Caroline McCoach, MD, PhD
Assistant Clinical Professor
Medicine
School of Medicine

Her primary research focus is on treatment of cancers driven by genetic mutations or alterations such as ALK, ROS1, EGFR, and others. She is also working to find treatments to prevent or delay the development of resistance to targeted therapies as well as increase the efficacy of standard targeted therapies by using rational combination treatments. She works closely with laboratory based researchers to develop new and improved treatments for lung cancer patients.

• Patient-Reported Outcomes with Selpercatinib Treatment Among Patients with RET-Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO-001 Trial.
  The oncologist 2022 Wirth LJ, Robinson B, Boni V, Tan DSW, McCoach C, Massarelli E, Hess LM, Jen MH, Kherani J, Olek E, Subbiah V
• In Response to: "Comparing Addition of Radiotherapy in EGFR- and ALK-Positive NSCLC With Brain Metastases: Are We Evaluating the Optimal Endpoint?"
  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2022 Thomas NJ, Myall NJ, Sun F, Patil T, Mushtaq R, Yu C, Sinha S, Pollom EL, Nagpal S, Camidge DR, Rusthoven CG, Braunstein SE, Wakelee HA, McCoach CE
• NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types.
  British journal of cancer 2021 Rolfo C, Drilon A, Hong D, McCoach C, Dowlati A, Lin JJ, Russo A, Schram AM, Liu SV, Nieva JJ, Nguyen T, Eshaghian S, Morse M, Gettinger S, Mobayed M, Goldberg S, Araujo-Mino E, Vidula N, Bardia A, …
• Brain Metastases in EGFR- and ALK-Positive NSCLC: Outcomes of Central Nervous System-Penetrant Tyrosine Kinase Inhibitors Alone Versus in Combination With Radiation.
  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2021 Thomas NJ, Myall NJ, Sun F, Patil T, Mushtaq R, Yu C, Sinha S, Pollom EL, Nagpal S, Camidge DR, Rusthoven CG, Braunstein SE, Wakelee HA, McCoach CE
• Therapeutic Advances in the Management of Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.
  Current treatment options in oncology 2021 Sun F, McCoach CE
• Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2021 Subbiah V, Gainor JF, Oxnard GR, Tan DSW, Owen DH, Cho BC, Loong HH, McCoach CE, Weiss J, Kim YJ, Bazhenova L, Park K, Daga H, Besse B, Gautschi O, Rolfo C, Zhu EY, Kherani JF, Huang X, Kang S, Drilon…
• A tyrosine kinase inhibitor-induced interferon response positively associates with clinical response in EGFR-mutant lung cancer.
  NPJ precision oncology 2021 Gurule NJ, McCoach CE, Hinz TK, Merrick DT, Van Bokhoven A, Kim J, Patil T, Calhoun J, Nemenoff RA, Tan AC, Doebele RC, Heasley LE
• Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy.
  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2021 Aredo JV, Mambetsariev I, Hellyer JA, Amini A, Neal JW, Padda SK, McCoach CE, Riess JW, Cabebe EC, Naidoo J, Abuali T, Salgia R, Loo BW, Diehn M, Han SS, Wakelee HA
• Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET-Positive Non-Small-Cell Lung Cancer.
  JCO precision oncology 2021 McCoach CE, Yu A, Gandara DR, Riess JW, Vang DP, Li T, Lara PN, Gubens M, Lara F, Mack PC, Beckett LA, Kelly K
• Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer.
  Annals of oncology : official journal of the European Society for Medical Oncology 2020 Lin JJ, Liu SV, McCoach CE, Zhu VW, Tan AC, Yoda S, Peterson J, Do A, Prutisto-Chang K, Dagogo-Jack I, Sequist LV, Wirth LJ, Lennerz JK, Hata AN, Mino-Kenudson M, Nardi V, Ou SI, Tan DS, Gainor JF
• Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer.
  The New England journal of medicine 2020 Drilon A, Oxnard GR, Tan DSW, Loong HHF, Johnson M, Gainor J, McCoach CE, Gautschi O, Besse B, Cho BC, Peled N, Weiss J, Kim YJ, Ohe Y, Nishio M, Park K, Patel J, Seto T, Sakamoto T, Rosen E, Shah MH,…
• Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing.
  Cell 2020 Maynard A, McCoach CE, Rotow JK, Harris L, Haderk F, Kerr DL, Yu EA, Schenk EL, Tan W, Zee A, Tan M, Gui P, Lea T, Wu W, Urisman A, Jones K, Sit R, Kolli PK, Seeley E, Gesthalter Y, Le DD, Yamauchi KA…
• Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations.
  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2020 Negrao MV, Raymond VM, Lanman RB, Robichaux JP, He J, Nilsson MB, Ng PKS, Amador BE, Roarty EB, Nagy RJ, Banks KC, Zhu VW, Ng C, Chae YK, Clarke JM, Crawford JA, Meric-Bernstam F, Ignatius Ou SH, …
• Role of MPR as an Early Signal for Efficacy in Neoadjuvant Studies.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Blakely CM, McCoach CE
• Tumor evolution in epidermal growth factor receptor mutated non-small cell lung cancer.
  Journal of thoracic disease 2020 Velazquez AI, McCoach CE
• Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Rotow JK, Gui P, Wu W, Raymond VM, Lanman RB, Kaye FJ, Peled N, Fece de la Cruz F, Nadres B, Corcoran RB, Yeh I, Bastian BC, Starostik P, Newsom K, Olivas VR, Wolff AM, Fraser JS, Collisson EA, …
• Engineering Multidimensional Evolutionary Forces to Combat Cancer.
  Cancer discovery 2019 McCoach CE, Bivona TG
• A Cautionary Analysis of Immunotherapy Prior to Targeted Therapy.
  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2019 McCoach CE
• Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins.
  Cancer research 2018 Neel DS, Allegakoen DV, Olivas V, Mayekar MK, Hemmati G, Chatterjee N, Blakely CM, McCoach CE, Rotow JK, Le A, Karachaliou N, Rosell R, Riess JW, Nichols R, Doebele RC, Bivona TG
• Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient With a MET Exon 14 Skipping Mutation.
  Clinical lung cancer 2018 Rotow JK, Woodard GA, Urisman A, McCoach CE, Bivona TG, Elicker BM, Jablons DM, Blakely CM
• Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer.
  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2018 Blumenthal GM, Bunn PA, Chaft JE, McCoach CE, Perez EA, Scagliotti GV, Carbone DP, Aerts HJWL, Aisner DL, Bergh J, Berry DA, Jarkowski A, Botwood N, Cross DAE, Diehn M, Drezner NL, Doebele RC, Blakely…
• First-line Chemotherapy Responsiveness and Patterns of Metastatic Spread Identify Clinical Syndromes Present Within Advanced KRAS Mutant Non-Small-cell Lung Cancer With Different Prognostic Significance.
  Clinical lung cancer 2018 Iams WT, Yu H, Shyr Y, Patil T, Horn L, McCoach C, Kelly K, Doebele RC, Camidge DR
• RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.
  Nature cell biology 2018 Nichols RJ, Haderk F, Stahlhut C, Schulze CJ, Hemmati G, Wildes D, Tzitzilonis C, Mordec K, Marquez A, Romero J, Hsieh T, Zaman A, Olivas V, McCoach C, Blakely CM, Wang Z, Kiss G, Koltun ES, Gill AL, …
• Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2018 McCoach CE, Le AT, Gowan K, Jones K, Schubert L, Doak A, Estrada-Bernal A, Davies KD, Merrick DT, Bunn PA, Purcell WT, Dziadziuszko R, Varella-Garcia M, Aisner DL, Camidge DR, Doebele RC
• Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2018 McCoach CE, Blakely CM, Banks KC, Levy B, Chue BM, Raymond VM, Le AT, Lee CE, Diaz J, Waqar SN, Purcell WT, Aisner DL, Davies KD, Lanman RB, Shaw AT, Doebele RC
• The evolving understanding of immunoediting and the clinical impact of immune escape.
  Journal of thoracic disease 2018 McCoach CE, Bivona TG
• The importance of the initial response to cancer treatment in predicting longer overall survival.
  Expert review of clinical pharmacology 2017 McCoach CE, Doebele RC
• Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers.
  Nature genetics 2017 Blakely CM, Watkins TBK, Wu W, Gini B, Chabon JJ, McCoach CE, McGranahan N, Wilson GA, Birkbak NJ, Olivas VR, Rotow J, Maynard A, Wang V, Gubens MA, Banks KC, Lanman RB, Caulin AF, St John J, Cordero …
• Acral Lentiginous Melanoma Harboring a ROS1 Gene Fusion With Clinical Response to Entrectinib.
  JCO precision oncology 2017 Couts KL, McCoach CE, Murphy D, Christiansen J, Turner J, Lewis KD, Robinson WA, Doebele RC
• Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy.
  Annals of oncology : official journal of the European Society for Medical Oncology 2017 McCoach CE, Blumenthal GM, Zhang L, Myers A, Tang S, Sridhara R, Keegan P, Pazdur R, Doebele RC, Kazandjian D
• PS01.68: Heterogeneous Clinical Syndromes Existing Within Patients with Stage IV KRAS Mutant Non-Small Cell Lung Cancer: Topic: Medical Oncology.
  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016 Iams WT, Yu H, Shyr Y, Patil T, Horn L, McCoach C, Kelly K, Doebele R, Camidge DR
• Osimertinib, a third-generation tyrosine kinase inhibitor targeting non-small cell lung cancer with EGFR T790M mutations.
  Drugs of today (Barcelona, Spain : 1998) 2016 McCoach CE, Jimeno A
• Neoadjuvant Oncogene-Targeted Therapy in Early Stage Non-Small-Cell Lung Cancer as a Strategy to Improve Clinical Outcome and Identify Early Mechanisms of Resistance.
  Clinical lung cancer 2016 McCoach CE, Bivona TG, Blakely CM, Doebele RC
• A Brief Report of the Status of Central Nervous System Metastasis Enrollment Criteria for Advanced Non-Small Cell Lung Cancer Clinical Trials: A Review of the ClinicalTrials.gov Trial Registry.
  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2015 McCoach CE, Berge EM, Lu X, Barón AE, Camidge DR
• Paraneoplastic Leukemoid Reaction as a Marker of Tumor Progression in Non-Small Cell Lung Cancer.
  Cancer treatment communications 2015 McCoach CE, Rogers JG, Dwyre DM, Jonas BA
• The minority report: targeting the rare oncogenes in NSCLC.
  Current treatment options in oncology 2014 McCoach CE, Doebele RC
• Adherence to guideline-recommended therapy is associated with decreased major adverse cardiovascular events and major adverse limb events among patients with peripheral arterial disease.
  Journal of the American Heart Association 2014 Armstrong EJ, Chen DC, Westin GG, Singh S, McCoach CE, Bang H, Yeo KK, Anderson D, Amsterdam EA, Laird JR
• Treatment paradigms in advanced non-small-cell lung cancer.
  Clinical advances in hematology & oncology : H&O 2013 McCoach CE, Kelly K
• Fungating mass as first presentation of advanced breast cancer.
  Journal of general internal medicine 2013 McCoach CE, Aronowitz P
• Gender-related variation in the clinical presentation and outcomes of critical limb ischemia.
  Vascular medicine (London, England) 2013 McCoach CE, Armstrong EJ, Singh S, Javed U, Anderson D, Yeo KK, Westin GG, Hedayati N, Amsterdam EA, Laird JR
• Systematic identification of balanced transposition polymorphisms in Saccharomyces cerevisiae.
  PLoS genetics 2009 Faddah DA, Ganko EW, McCoach C, Pickrell JK, Hanlon SE, Mann FG, Mieczkowska JO, Jones CD, Lieb JD, Vision TJ
• Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose- and sequence-dependent manner.
  BJU international 2009 Flaig TW, Su LJ, McCoach C, Li Y, Raben D, Varella-Garcia M, Bemis LT